Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Following the expiration of confidentiality deferrals, Celltrion disclosed that its 100% US subsidiary, Celltrion USA, Inc., has signed a definitive agreement to acquire Imclone Systems LLC from an Eli Lilly subsidiary for approx. KRW 460.0B (USD 330M).
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Execution of Exclusivity Agreement for Acquisition of US API Facility Entity (Preferred Bidder Selection) (Correction)
- Original Filing & Correction Date: July 29, 2025 / September 23, 2025
- Reason for Correction: Unmasking of deferred matters (Counterparty and Transaction Amount) upon definitive agreement execution
- Purpose of Acquisition:
- Mitigating US export pharmaceutical tariff risks
- Securing cost competitiveness by establishing local US manufacturing capacity
- Definitive Agreement Details:
- Acquiring Entity: Celltrion USA, Inc. (100% US subsidiary of Celltrion)
- Counterparty: Imclone Systems Holdings, Inc. (Subsidiary of Eli Lilly and Company / Eli Lilly co-signed as guarantor)
- Target Entity: Imclone Systems LLC (US cGMP API manufacturing facility entity)
- Acquisition Amount: KRW 460,020,000,000 (approx. KRW 460.0B / USD 330,000,000, applied exchange rate: USD/KRW 1,394.00)
- Future Plans & Expected Impact:
- Capacity expansion and cost optimization post-acquisition
- Immediate revenue generation via CMO production of existing products
- Maximizing R&D synergies by strengthening local research capabilities
- Targeted completion of acquisition procedures within the year
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Definitive Agreement Execution and Year-End Deal Closing Progress
This corrected disclosure reveals the previously withheld details—specifically the counterparty (an Eli Lilly subsidiary) and total purchase price (approx. KRW 460.0B)—for Celltrion’s acquisition of a US API manufacturing facility following the signing of the definitive agreement. With the contract signed, it is key to monitor the final closing of the transaction within the scheduled timeframe. Tracking deal completion confirms operational progress toward establishing US manufacturing capabilities and mitigating tariff exposure. Final closing status and post-acquisition updates can be verified through future regulatory filings or upcoming periodic reports (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
